Genomic alterations in CRKL appear to be predictive of response to Src inhibitors in preclinical studies with gastric and NSCLC cell lines (Figure 2).[21] Of note, chronic myeloid leukemia (CML) cell lines have the highest levels of CRKL mRNA expression according to Cancer Cell Line Encyclopedia (data base accessed on October 20th 2014). This evidence concerns the gene CRKL and non-small cell lung carcinoma.